Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ticarcillin sodium, quantity: 3.3 g (equivalent: ticarcillin, qty 3 g); potassium clavulanate, quantity: 119.2 g (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - timentin is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of klebsiella pneumoniae, e.coli, staphylococcus aureus and pseudomonas aeruginosa. lower respiratory infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, haemophilus influenzae and klebsiella pneumoniae. bone and joint infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus. skin and skin structure infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, klebsiella pneumoniae and e. coli. urinary tract infections cases caused by beta-lactamase producing susceptible organisms including strains of e.coli, klebsiella pneumoniae, pseudomonas aeruginosa and staphylococcus au

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage);  ; ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - powder for injection - active: potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage)   ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - the treatment of infections caused by susceptible strains of organisms in the conditions listed below: - septicaemia (including bacteraemia) - lower respiratory tract infections - bone and joint infections - skin and skin structure infections - urinary tract infections - gynaecological infections - surgical prophylaxis appropriate culture and susceptibility tests should be performed in order to isolate and identify organisms causing infection and to determine their susceptibility to timentin. susceptibility to timentin will vary with geography and time and local succeptibility data should be consulted where available. in certain infections, when the causative organisms are unknown, timentin may be administered in conjunction with an aminoglycoside as initial therapy. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal hysterectomy, abdominal surgery, and colorectal surgery when there is a significant risk of postoperative infection or where occurrence of postoperative infection is considered to be especially serious.

Australia - English - Department of Health (Therapeutic Goods Administration)

potassium clavulanate; ticarcillin sodium -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

laboratoires delbert - potassium clavulanate; ticarcillin sodium - powder for solution for infusion - 200mg ; 3gram

Canada - English - Health Canada

glaxosmithkline inc - ticarcillin (ticarcillin disodium); clavulanic acid (clavulanate potassium) - powder for solution - 3g; 100mg - ticarcillin (ticarcillin disodium) 3g; clavulanic acid (clavulanate potassium) 100mg - extended-spectrum penicillins

Canada - English - Health Canada

glaxosmithkline inc - ticarcillin (ticarcillin disodium); clavulanic acid (potassium clavulanate) - powder for solution - 30g; 1g - ticarcillin (ticarcillin disodium) 30g; clavulanic acid (potassium clavulanate) 1g - extended-spectrum penicillins

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.

Ireland - English - HPRA (Health Products Regulatory Authority)

smithkline beecham pharm ltd - ticarcillin disodium clavulanate potassium - 0.8 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

smithkline beecham pharm ltd - ticarcillin disodium clavulanate potassium - solution for infusion - 3.2